Initial characterization of immune microenvironment in pheochromocytoma and paraganglioma

• DOI: 10.3389/fgene.2022.1022131
• Publication Date: 2022-12-07T05:35:25Z
• Authors: Bo Jin; Wencong Han; Jingjing Guo; Jie Tian; Shiming He; Yanqing Gong; Jingcheng Zhou; Qun He; Qi Shen; Zheng Zhang
• Keywords: PD-L1; Immunology; immune microenvironment; Pheochromocytoma; Cancer research; QH426-470; Cancer Immunotherapy; Paraganglioma; 03 medical and health sciences; 0302 clinical medicine; Pheochromocytoma and Paraganglioma; Health Sciences; Genetics; Tumor Microenvironment; Pathology; Gliomas; Internal medicine; FOS: Clinical medicine; CD8; pheochromocytoma; 3. Good health; Immune system; Oncology; Tumor microenvironment; FOS: Biological sciences; Medicine; Biomarkers for Immunotherapy; microsatellite instability; Surgery; immunotherapy; Immunotherapy

Due to fewer adverse events, faster onset of action, and longer durable responses compared chemotherapy, immunotherapy has been widely used treat advanced solid tumors. Moreover, can improve the autoimmune status, thus allowing patients benefit from treatment in long term. The immune microenvironment status is closely associated with response chemotherapies. Here, we analyzed characteristics pheochromocytoma paraganglioma (PPGL). Immunohistochemistry showed that PD-L1 sparely expressed PPGL low positive rates expression levels, an pattern, is, not correlated tumor malignancy. level intratumoral CD4 + CD8 lymphocyte infiltration low, suggesting may be “immune desertification” or rejection” states which prevented, rendering less effective. In sum, our results indicate a microsatellite-stable mutational burden (TMB) weak neoantigen production, poor antigenicity, hinting at